VARIAGENICS announces issuance of United States patent for Mthfr gene.
The methylenetetrahydrofolate reductase genotype has been shown to affect blood levels of homocysteine and folates, which in turn affect risk of a number of diseases and disorders including cardiovascular and central nervous system diseases, and cancer. The issued claims cover methods for determining methylenetetrahydrofolate reductase levels based upon genotype, as well as methods for associating methylenetetrahydrofolate reductase deficiency with the risk of cardiovascular disease, cancers, neurological disorders, and disorders influenced by folic acid metabolism, or the prognosis of patients with these diseases. It is believed that such an association may lead to the development of specific genetic diagnostic tests useful in determining diagnosis, prognosis and therapeutic benefit of treatment regimens for patients with such disorders.
"VARIAGENICS is intensively investigating pharmacologically important pathways, and methylenetetrahydrofolate reductase is a key e nzyme in the folate pathway," said Vincent P. Stanton, PhD, vice president and principal scientist at VARIAGENICS. "Folate metabolism plays an important role in both pharmacokinetic and pharmacodynamic behavior of a variety of drugs. The McGill research collaboration and the licensing of the methylenetetrahydrofolate reductase patent allows VARIAGENICS to move ahead with the continued development of new diagnostic tools that ultimately may be useful for both disease risk assessment and pharmacogenetic purposes."
"We believe MTHFR is a very significant gene because the metabolism of folate is central to so many different metabolic processes, and consequently is associated with a variety of diseases," said Dr. Rima Rozen of McGill University.
VARIAGENICS through its proprietary technology platform, identifies clinically important variances (single-nucleotide polymorphisms) in genes that affect drug action and applies this information to the discovery and development of new pharmaceutical products, diagnostic products, and disease-management practices.
|Printer friendly Cite/link Email Feedback|
|Comment:||VARIAGENICS announces issuance of United States patent for Mthfr gene.|
|Publication:||BIOTECH Patent News|
|Article Type:||Brief Article|
|Date:||Jun 1, 2000|
|Previous Article:||Biosyn receives notice of allowance for key patent addition to C31g technology platform.|
|Next Article:||Pathobiotek reports receipt of 'notice of allowability' for a patent on Activating Virus.|